Filing Flows › BioMarin Pharmaceutical (BMRN) › Net income
BioMarin Pharmaceutical (BMRN) net income by quarter
BioMarin Pharmaceutical's net income was $44.8M in Q2 2026 (second quarter 2026), -58% from Q1 2026. Over the last 4 quarters it ranged from $44.8M (Q2 2026) to $241M (Q2 2025).
| Quarter | Net income | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $44.8M | -58% | -81% |
| Q1 2026 | $106M | -56% | -43% |
| Q2 2025 | $241M | +30% | — |
| Q1 2025 | $186M | — | — |
Q2 2026 at a glance
BioMarin Pharmaceutical, Q2 2026: revenue $990M (+20% year over year), operating margin 11.2%, net earnings $44.8M, operating cash flow $168M. The chart follows the revenue to costs, profit and cash.
Questions
What is BioMarin Pharmaceutical's net income?
BioMarin Pharmaceutical's net income was $44.8M in Q2 2026 (second quarter 2026), -58% from Q1 2026.
How has BioMarin Pharmaceutical's net income changed?
Over the last 4 quarters it ranged from $44.8M (Q2 2026) to $241M (Q2 2025).
Q2 2026 results → · How BioMarin Pharmaceutical makes money →